CR9910A - Antagonistas del receptor 3 de la histamina - Google Patents
Antagonistas del receptor 3 de la histaminaInfo
- Publication number
- CR9910A CR9910A CR9910A CR9910A CR9910A CR 9910 A CR9910 A CR 9910A CR 9910 A CR9910 A CR 9910A CR 9910 A CR9910 A CR 9910A CR 9910 A CR9910 A CR 9910A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compound
- formula
- antagonists
- histamine
- receiver
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Esta invencion esta drigida a un compuesto de formula I, como se define en la presente memoria, o una sal farmaceuticamente aceptable del mismo; una composicion farmaceutica que contiene un compuesto de formula I, un procedimiento de preparacion de un compuesto de formula I, un metodo de tratamiento de un trastorno o enfermnedad que se puede tratar antagonizando los receptores H3 de la histamina, el metodo comprende administrar a un mamifero que necesita tal tratamiento un compuesto de formula I como se describio anteriormente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73099605P | 2005-10-27 | 2005-10-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR9910A true CR9910A (es) | 2008-05-16 |
Family
ID=37776539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9910A CR9910A (es) | 2005-10-27 | 2008-04-23 | Antagonistas del receptor 3 de la histamina |
Country Status (40)
Country | Link |
---|---|
US (2) | US8158673B2 (es) |
EP (1) | EP1951660B1 (es) |
JP (2) | JP4319245B2 (es) |
KR (1) | KR101025358B1 (es) |
CN (1) | CN101296898B (es) |
AP (1) | AP2403A (es) |
AR (1) | AR056879A1 (es) |
AU (1) | AU2006307645B2 (es) |
BR (1) | BRPI0617797A2 (es) |
CA (1) | CA2621323C (es) |
CR (1) | CR9910A (es) |
CU (1) | CU23806B7 (es) |
DK (1) | DK1951660T3 (es) |
DO (1) | DOP2006000239A (es) |
EA (1) | EA013602B1 (es) |
EC (1) | ECSP088373A (es) |
ES (1) | ES2444370T3 (es) |
GE (1) | GEP20104937B (es) |
GT (1) | GT200600471A (es) |
HK (1) | HK1124831A1 (es) |
HN (1) | HN2006036385A (es) |
HR (1) | HRP20140061T1 (es) |
IL (1) | IL189866A (es) |
MA (1) | MA29888B1 (es) |
MY (1) | MY145001A (es) |
NI (1) | NI200800132A (es) |
NL (1) | NL1032713C2 (es) |
NO (1) | NO20082264L (es) |
NZ (1) | NZ566488A (es) |
PE (1) | PE20070720A1 (es) |
PL (1) | PL1951660T3 (es) |
PT (1) | PT1951660E (es) |
RS (2) | RS53153B (es) |
SI (1) | SI1951660T1 (es) |
TN (1) | TNSN08150A1 (es) |
TW (1) | TWI318206B (es) |
UA (1) | UA88719C2 (es) |
UY (1) | UY29882A1 (es) |
WO (1) | WO2007049123A1 (es) |
ZA (1) | ZA200803130B (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8158673B2 (en) * | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
NZ577951A (en) * | 2007-01-22 | 2012-02-24 | Pfizer Prod Inc | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
WO2008108445A1 (ja) | 2007-03-07 | 2008-09-12 | Takeda Pharmaceutical Company Limited | ベンゾオキサゼピン誘導体およびその用途 |
ES2442926T3 (es) | 2007-08-22 | 2014-02-14 | Astrazeneca Ab | Derivados de ciclopropilamida `978 |
MX2010006162A (es) * | 2007-12-07 | 2010-06-25 | Pfizer | Sal tosilato de una trans-n-isobutil-3-fluoro-3-[3-fluoro-4-(pirro lidin-1-il-metil)fenil]ciclobutanocarboxamida. |
WO2009135842A1 (en) * | 2008-05-08 | 2009-11-12 | Evotec Neurosciences Gmbh | Azetidines and cyclobutanes as histamine h3 receptor antagonists |
TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
MX336333B (es) | 2010-02-18 | 2016-01-15 | Astrazeneca Ab | Nueva forma cristalina de un derivado de ciclopropilbenzamida. |
ES2602794T3 (es) | 2011-03-31 | 2017-02-22 | Pfizer Inc | Piridinonas bicíclicas novedosas |
WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
JP6043355B2 (ja) | 2011-08-31 | 2016-12-14 | ファイザー・インク | ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
WO2013164730A1 (en) | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2. |
JP6189948B2 (ja) | 2012-06-29 | 2017-08-30 | ファイザー・インク | LRRK2阻害薬としての新規な4−(置換アミノ)−7H−ピロロ[2,3−d]ピリミジン |
WO2014045162A1 (en) | 2012-09-20 | 2014-03-27 | Pfizer Inc. | ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-ANIME COMPOUNDS |
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
EP2931731A1 (en) | 2012-12-11 | 2015-10-21 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
CA2893333C (en) | 2012-12-19 | 2017-10-24 | Pfizer Inc. | Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
JP2016507551A (ja) | 2013-02-13 | 2016-03-10 | ファイザー・インク | ヘテロアリール置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
BR112015019276A2 (pt) | 2013-02-19 | 2017-07-18 | Pfizer | compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios |
ES2742078T3 (es) | 2013-10-04 | 2020-02-13 | Pfizer | Piridonas bicíclicas novedosas como moduladores de gamma-secretasa |
US9695171B2 (en) | 2013-12-17 | 2017-07-04 | Pfizer Inc. | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors |
MX369074B (es) | 2014-04-01 | 2019-10-28 | Pfizer | Cromeno y 1,1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de la gamma secretasa. |
MD20160105A2 (ro) | 2014-04-10 | 2017-03-31 | Pfizer Inc. | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide |
JP6713982B2 (ja) | 2014-07-24 | 2020-06-24 | ファイザー・インク | ピラゾロピリミジン化合物 |
ES2733502T3 (es) | 2014-08-06 | 2019-11-29 | Pfizer | Compuestos de imidazopiridazina |
PE20171318A1 (es) | 2015-02-03 | 2017-09-07 | Pfizer | Ciclopropabenzofuranil-piridopirazindionas novedosas |
EP3766885B1 (en) | 2015-06-17 | 2022-05-25 | Pfizer Inc. | Tricyclic compounds and their use as phosphodiesterase inhibitors |
RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
JP2018534251A (ja) | 2015-09-24 | 2018-11-22 | ファイザー・インク | Bace阻害剤として有用なn−[2−(3−アミノ−2,5−ジメチル−1,1−ジオキシド−5,6−ジヒドロ−2h−1,2,4−チアジアジン−5−イル)−1,3−チアゾール−4−イル]アミド |
AU2016325665A1 (en) | 2015-09-24 | 2018-03-08 | Pfizer Inc. | N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides |
JP2018531924A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | テトラヒドロピラノ[3,4−d][1,3]オキサジン誘導体、およびbace阻害剤としてのその使用 |
CN108699080B (zh) | 2016-02-23 | 2021-05-14 | 辉瑞公司 | 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物 |
DK3478679T3 (da) | 2016-07-01 | 2021-06-21 | Pfizer | 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme |
AU2018230236B2 (en) | 2017-03-10 | 2022-05-19 | Pfizer Inc. | Novel imidazo[4,5-c]quinoline derivatives as LRRK2 inhibitors |
CA3056027A1 (en) | 2017-03-10 | 2018-09-13 | Pfizer Inc. | Cyclic substituted imidazo[4,5-c]quinoline derivatives |
WO2018226992A1 (en) | 2017-06-07 | 2018-12-13 | Adrx, Inc. | Tau aggregation inhibitors |
FI3642202T3 (fi) | 2017-06-22 | 2023-03-01 | Dihydro-pyrrolo-pyridiinijohdannaisia | |
US11453701B2 (en) | 2017-08-18 | 2022-09-27 | Adrx, Inc. | Tau aggregation peptide inhibitors |
DK3768669T3 (da) | 2018-03-23 | 2023-04-24 | Pfizer | Piperazinazaspiroderivater |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6559140B2 (en) * | 2000-03-09 | 2003-05-06 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
WO2002076925A2 (en) | 2001-03-23 | 2002-10-03 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
US7671047B2 (en) * | 2002-06-19 | 2010-03-02 | Sanofi-Aventis Deutschland Gmbh | Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
JP2004131497A (ja) * | 2002-09-18 | 2004-04-30 | Satoshi Shuto | シスシクロプロパン誘導体 |
MXPA06001053A (es) * | 2003-07-29 | 2006-04-11 | Novo Nordisk As | Piridazinil-piperazinas y su uso como ligandos del receptor de histamina h3. |
CN1902177A (zh) * | 2003-09-22 | 2007-01-24 | 万有制药株式会社 | 新哌啶衍生物 |
EP1720847A1 (en) | 2004-02-02 | 2006-11-15 | Pfizer Products Incorporated | Histamine-3 receptor modulators |
JP4777974B2 (ja) * | 2004-04-01 | 2011-09-21 | イーライ リリー アンド カンパニー | ヒスタミンh3受容体作用物質、製剤および治療的使用 |
US7456164B2 (en) * | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
EP1595881A1 (en) * | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
ATE488496T1 (de) | 2005-06-22 | 2010-12-15 | Pfizer Prod Inc | Histamin-3-rezeptorantagonisten |
US8158673B2 (en) * | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
NZ577951A (en) * | 2007-01-22 | 2012-02-24 | Pfizer Prod Inc | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
-
2006
- 2006-10-13 US US11/549,175 patent/US8158673B2/en not_active Expired - Fee Related
- 2006-10-16 SI SI200631724T patent/SI1951660T1/sl unknown
- 2006-10-16 AP AP2008004401A patent/AP2403A/xx active
- 2006-10-16 ES ES06809114.9T patent/ES2444370T3/es active Active
- 2006-10-16 NZ NZ566488A patent/NZ566488A/en not_active IP Right Cessation
- 2006-10-16 JP JP2008537213A patent/JP4319245B2/ja not_active Expired - Fee Related
- 2006-10-16 BR BRPI0617797-2A patent/BRPI0617797A2/pt not_active IP Right Cessation
- 2006-10-16 AU AU2006307645A patent/AU2006307645B2/en not_active Ceased
- 2006-10-16 RS RS20140034A patent/RS53153B/en unknown
- 2006-10-16 EA EA200800946A patent/EA013602B1/ru not_active IP Right Cessation
- 2006-10-16 GE GEAP200610660A patent/GEP20104937B/en unknown
- 2006-10-16 UA UAA200802656A patent/UA88719C2/ru unknown
- 2006-10-16 CN CN2006800399763A patent/CN101296898B/zh not_active Expired - Fee Related
- 2006-10-16 KR KR1020087009991A patent/KR101025358B1/ko not_active IP Right Cessation
- 2006-10-16 RS RSP-2008/0173A patent/RS20080173A/sr unknown
- 2006-10-16 CA CA2621323A patent/CA2621323C/en not_active Expired - Fee Related
- 2006-10-16 EP EP06809114.9A patent/EP1951660B1/en active Active
- 2006-10-16 DK DK06809114.9T patent/DK1951660T3/da active
- 2006-10-16 PL PL06809114T patent/PL1951660T3/pl unknown
- 2006-10-16 PT PT68091149T patent/PT1951660E/pt unknown
- 2006-10-16 WO PCT/IB2006/002977 patent/WO2007049123A1/en active Application Filing
- 2006-10-20 NL NL1032713A patent/NL1032713C2/nl not_active IP Right Cessation
- 2006-10-24 PE PE2006001288A patent/PE20070720A1/es not_active Application Discontinuation
- 2006-10-25 UY UY29882A patent/UY29882A1/es not_active Application Discontinuation
- 2006-10-25 AR ARP060104658A patent/AR056879A1/es active IP Right Grant
- 2006-10-25 GT GT200600471A patent/GT200600471A/es unknown
- 2006-10-26 HN HN2006036385A patent/HN2006036385A/es unknown
- 2006-10-26 DO DO2006000239A patent/DOP2006000239A/es unknown
- 2006-10-26 TW TW095139560A patent/TWI318206B/zh not_active IP Right Cessation
-
2008
- 2008-02-28 IL IL189866A patent/IL189866A/en not_active IP Right Cessation
- 2008-04-02 TN TNP2008000150A patent/TNSN08150A1/fr unknown
- 2008-04-09 ZA ZA200803130A patent/ZA200803130B/xx unknown
- 2008-04-15 EC EC2008008373A patent/ECSP088373A/es unknown
- 2008-04-23 CU CU20080069A patent/CU23806B7/es not_active IP Right Cessation
- 2008-04-23 CR CR9910A patent/CR9910A/es not_active Application Discontinuation
- 2008-04-24 MY MYPI20081265A patent/MY145001A/en unknown
- 2008-04-25 MA MA30879A patent/MA29888B1/fr unknown
- 2008-04-28 NI NI200800132A patent/NI200800132A/es unknown
- 2008-05-16 NO NO20082264A patent/NO20082264L/no not_active Application Discontinuation
-
2009
- 2009-03-03 HK HK09101990.9A patent/HK1124831A1/xx not_active IP Right Cessation
- 2009-03-10 JP JP2009055839A patent/JP5064427B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-09 US US13/415,944 patent/US8389743B2/en not_active Expired - Fee Related
-
2014
- 2014-01-20 HR HRP20140061TT patent/HRP20140061T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR9910A (es) | Antagonistas del receptor 3 de la histamina | |
MX2021001752A (es) | Compuestos de pirrolo-dipiridina. | |
CR10383A (es) | Derivados triazolopirazina. | |
EA201170473A1 (ru) | Морфинановые соединения | |
CR9721A (es) | Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos | |
ECSP055867A (es) | Derivados de pirrolopirimidina | |
JO2848B1 (en) | Organic compounds | |
SV2011004077A (es) | Derivados aminobutiricos sustituidos como inhibidores de neprilisina | |
EA201270043A1 (ru) | Замещенные производные изоиндолин-1,3-диона | |
ECSP055935A (es) | Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension | |
EA201270570A1 (ru) | Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90 | |
ECSP056134A (es) | Derivados de quinuclidina que se enlazan con los receptores muscarínicos m3 | |
MA32784B1 (fr) | Composes aryles substitues par heterocycle comme inhibiteurs de hif | |
MD20140059A2 (en) | Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases | |
UY29710A1 (es) | Benzimidazoles tricíclicos y su uso como moduladores de receptores metabotrópicos de glutamato | |
MX2012004848A (es) | Compuestos heterociclicos triciclicos. | |
AR060089A1 (es) | Tratamiento del dolor | |
GT200600160A (es) | Tratamiento del dolor | |
UY33278A (es) | Pirimidinas sustituidas como antagonistas del receptor de la protaglandina d2 | |
DE602005007765D1 (de) | Neue indol- oder benzimidazol-derivate | |
MX2010008690A (es) | Farmacoforos duales - antagonistas muscarinicos de pde4. | |
CO6300937A2 (es) | Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu | |
MY158069A (en) | Tricyclic compound and pharmaceutical use thereof | |
DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
EA201270347A1 (ru) | Производные апогоссиполона в качестве противоопухолевых агентов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |